How the RNA therapeutics sector is shifting focus toward manufacturing scalability challenges

Codexis, Inc. highlighted new advances in RNA therapeutic manufacturing at TIDES USA 2026, including full-length small interfering RNA synthesis with stereochemical control using its ECO Synthesis Manufacturing Platform. The biotechnology company also disclosed progress toward fully enzymatic RNA synthesis beginning from a single nucleotide, a development that could reduce dependence on chemically synthesized starter oligonucleotides as RNA drug developers increasingly prioritize industrial-scale production efficiency, manufacturing flexibility, and long-term cost optimization.

The announcement matters because the RNA therapeutics market is entering a new phase where manufacturing economics may become just as strategically important as scientific innovation. Over the past decade, the sector focused heavily on delivery systems, target validation, and clinical proof-of-concept. As more RNA interference therapies move into broader commercial indications, investors and pharmaceutical manufacturers are increasingly asking whether existing production systems can support industrial-scale demand without creating major cost, supply chain, or operational bottlenecks.

Why large-scale RNA therapeutic commercialization is forcing the industry to rethink manufacturing infrastructure strategies

The RNA therapeutics industry has matured rapidly from a niche scientific category into a commercially significant pharmaceutical segment. Approved RNA interference therapies have already demonstrated that gene-silencing approaches can produce clinically meaningful outcomes across several disease categories, particularly in liver-targeted disorders.

That success has changed the conversation across the sector. Early-stage biotechnology companies once focused primarily on demonstrating therapeutic viability. Now, commercial scalability is becoming a defining challenge.

Many existing oligonucleotide manufacturing systems were originally designed for relatively small patient populations where production complexity and high cost structures were manageable. However, as developers pursue larger chronic disease markets, manufacturing intensity rises substantially. Higher patient volumes require greater throughput, more efficient purification systems, and increasingly reliable production consistency.

This is where Codexis, Inc. is attempting to reposition the conversation. Rather than focusing solely on therapeutic discovery, the company is emphasizing industrial manufacturing architecture as a potential competitive differentiator for the next phase of RNA therapeutics expansion.

Industry analysts increasingly believe manufacturing infrastructure could become one of the most strategically valuable layers within the broader RNA ecosystem. Companies capable of reducing cost of goods, improving scalability, and simplifying production workflows may gain leverage across licensing partnerships, contract manufacturing agreements, and long-term pharmaceutical supply chains.

How stereochemical control could become an increasingly important differentiator in siRNA manufacturing economics

One of the more technically significant aspects of Codexis, Inc.’s presentation involved controlled phosphorothioate stereochemistry during full-length small interfering RNA synthesis. Phosphorothioate linkages are commonly used in oligonucleotide therapeutics because they improve molecular stability and durability inside the body. However, controlling stereochemistry across those linkages remains difficult using traditional chemistry-based synthesis approaches.

Conventional phosphoramidite manufacturing processes often generate mixtures of stereoisomers that can introduce variability into the final therapeutic product. While the industry has tolerated those limitations historically, the push toward higher-volume manufacturing and improved product optimization is increasing interest in stereochemical precision.

Industry observers note that stereochemical consistency may eventually influence potency, tolerability, and dose efficiency. If manufacturers can produce more uniform RNA molecules with greater biological precision, the long-term economics of RNA therapies could improve materially. That possibility explains why stereochemistry is drawing increasing attention from RNA interference developers, particularly those attempting to optimize next-generation therapies for larger patient populations.

Drug development executives participating in Codexis, Inc.’s TIDES USA panel discussion suggested stereochemical control could eventually support higher active pharmaceutical ingredient concentrations and potentially improve administration flexibility. Those advantages remain largely theoretical at this stage, but they reflect a broader shift in how manufacturers are evaluating process innovation.

Still, skepticism remains warranted. The RNA therapeutics industry does not yet possess extensive long-term commercial evidence demonstrating that stereochemically controlled oligonucleotides consistently outperform highly optimized conventional products across multiple therapeutic categories.

Why enzymatic RNA production platforms are gaining attention as sustainability and cost pressures intensify

Traditional oligonucleotide synthesis relies heavily on solvent-intensive chemistry workflows that require extensive purification and generate substantial material waste. As manufacturing volumes increase, those processes become more resource-intensive and environmentally burdensome. Codexis, Inc. is attempting to position its ECO Synthesis Manufacturing Platform as an alternative approach centered on aqueous enzymatic processing rather than heavily solvent-dependent chemistry.

The company reported more than a 50% reduction in global warming potential relative to conventional synthetic approaches, including approximately 2.7-fold lower global warming potential on an input materials basis. Sustainability metrics alone are unlikely to drive pharmaceutical manufacturing decisions, but environmental efficiency is becoming increasingly relevant as major pharmaceutical companies face growing pressure around supply chain sustainability and operational resource consumption.

More importantly, enzymatic manufacturing systems may eventually reduce infrastructure complexity if they prove commercially scalable. Aqueous production workflows could simplify purification processes, lower solvent handling requirements, and potentially reduce overall manufacturing costs over time.

However, pharmaceutical manufacturing transitions are historically slow and conservative. Regulatory agencies remain deeply familiar with traditional oligonucleotide synthesis systems, and manufacturers are reluctant to overhaul validated production processes without extensive operational evidence.

How fully enzymatic fragment synthesis could influence future RNA assembly workflows across the industry

Another strategically important aspect of Codexis, Inc.’s announcement involved its progress toward initiating enzymatic RNA synthesis from a single nucleotide. Current enzymatic workflows frequently depend on chemically synthesized starter oligonucleotides to initiate nucleotide extension. Eliminating that requirement could streamline manufacturing architectures significantly.

The importance becomes larger when viewed through the lens of fragment ligation strategies. As RNA therapeutics grow more sophisticated, fragment-based assembly methods are attracting greater interest because they may improve flexibility and reduce inefficiencies associated with producing longer oligonucleotide chains directly. Codexis, Inc. appears to be positioning its engineered ligases and enzymatic synthesis technologies as complementary parts of a broader integrated manufacturing framework.

Industry scientists increasingly believe ligation-driven assembly methods may become important for next-generation RNA therapeutic scalability. Fully enzymatic fragment production could theoretically reduce purification burdens, improve process efficiency, and support more modular manufacturing systems.

Even so, major operational questions remain unresolved. The industry has not yet seen extensive commercial evidence proving that enzymatic manufacturing systems can consistently outperform optimized chemistry-based production across large-scale therapeutic deployment. Manufacturing reproducibility, lot consistency, impurity characterization, and industrial reliability will remain central areas of scrutiny for regulators and pharmaceutical manufacturers evaluating these technologies.

Why investor attention is increasingly shifting from RNA therapeutic science toward industrial execution risks

Investor sentiment across the RNA therapeutics sector has evolved noticeably over the past several years. Earlier enthusiasm often centered on scientific novelty and platform potential. Today, institutional investors are paying closer attention to commercialization infrastructure, manufacturing economics, and long-term operational scalability.

That shift reflects a broader maturation process occurring across the industry. As RNA therapeutics move from experimental platforms toward commercially validated pharmaceutical categories, investors are increasingly evaluating whether companies possess the manufacturing capabilities necessary to support sustained growth.

Infrastructure-focused biotechnology companies may therefore attract growing strategic interest because they enable broader ecosystem expansion rather than depending entirely on the success of individual therapeutic assets.

Codexis, Inc. appears to be positioning itself within that infrastructure layer of the market. If enzymatic RNA manufacturing becomes commercially viable at scale, the company could benefit from wider adoption across multiple RNA therapeutic programs rather than relying on a single clinical asset.

At the same time, execution risk remains substantial. Manufacturing technology adoption cycles are often slower than early-stage investor enthusiasm suggests, particularly within highly regulated pharmaceutical production environments.

Key takeaways on what this development means for the company, its competitors, and the industry

• Codexis, Inc. is attempting to position manufacturing infrastructure, rather than therapeutic discovery alone, as a future competitive advantage within RNA therapeutics.
• The RNA therapeutics sector is increasingly shifting attention toward scalability, cost efficiency, and industrial manufacturing reliability.
• Controlled phosphorothioate stereochemistry may become more strategically important as RNA interference therapies expand into larger patient populations.
• Enzymatic manufacturing workflows could eventually reduce solvent dependence, purification complexity, and environmental burden across oligonucleotide production.
• Fragment ligation strategies are gaining industry attention as developers pursue more scalable RNA assembly methods.
• Regulatory acceptance and large-scale manufacturing reproducibility remain critical unresolved challenges for enzymatic production systems.
• Investor focus across RNA therapeutics is increasingly moving beyond platform science toward commercialization infrastructure and operational execution.
• Companies capable of industrializing RNA production efficiently may gain long-term leverage across partnerships, licensing, and pharmaceutical supply chains.